Scholarlink

<p>Written promotional materials from pharmaceutical companies continue to influence prescribing behaviour despite evolving regulatory oversight. Recent evidence from the European Journal of Clinical Pharmacology highlights persistent structural limitations in how promotional claims are framed and governed. This correspondence critically examines these findings within the context of contemporary clinical pharmacology, global prescribing pressures, and emerging digital promotion ecosystems. We identify a governance gap between content compliance and evidentiary accountability, and propose an Evidence-Linked Promotion Dossier framework to improve transparency, traceability, and currency of promotional claims. Strengthening evidence linkage in promotion has the potential to support rational prescribing, reduce low-value drug use, and enhance global medicines governance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correspondence: Strengthening evidence traceability in written drug promotion to support rational prescribing

  • 期刊论文

  • 发表日期：

    2026年6月20日

查看全文
  • M. Vijayasimha,
  • M. Srikanth

摘要

Written promotional materials from pharmaceutical companies continue to influence prescribing behaviour despite evolving regulatory oversight. Recent evidence from the European Journal of Clinical Pharmacology highlights persistent structural limitations in how promotional claims are framed and governed. This correspondence critically examines these findings within the context of contemporary clinical pharmacology, global prescribing pressures, and emerging digital promotion ecosystems. We identify a governance gap between content compliance and evidentiary accountability, and propose an Evidence-Linked Promotion Dossier framework to improve transparency, traceability, and currency of promotional claims. Strengthening evidence linkage in promotion has the potential to support rational prescribing, reduce low-value drug use, and enhance global medicines governance.